Cardiac troponins, natriuretic peptides, and h-FABP are recommended biomarkers for comprehensive risk stratification in pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Supports guideline-recommended biomarker integration in PE risk stratification; leaves open optimal thresholds and outcome impact.
Ideally, biomarkers should be part of a comprehensive risk stratification algorithm used together with clinical risk scores as a basis, and/or imaging. For this purpose, cardiac troponins, including high-sensitivity troponin generations, natriuretic peptides, and h-FABP (heart-type fatty acid-binding protein) are currently recommended in guidelines. There is emerging evidence for several novel biomarkers that require further validation before being applied in clinical practice.
No takes yet. Share an insight, caveat, or question.
Giannitsis et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: